GT BiopharmaGTBP
13F holders, Q2 2025 (June 30)21holders +1
4new positions
3sold out
1famous investor
$3.58avg. 13F price*
At the end of Q2 2025, 21 institutions reported holding GT Biopharma Inc. (GTBP) in their 13F filings, up 1 from Q1 2025. 4 opened new positions and 3 sold out. The largest holders were Bank of Montreal ($331K), Renaissance Technologies ($94K) and Geode Capital Management, LLC ($85K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- GT Biopharma Inc.
- CUSIP
- 36254L308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $98K |
| Exits | 3 | $45K |
All 13F filers, Q1 2025 → Q2 2025: 119,636 shares bought and 20,648 shares sold, net +98,988 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Bank of Montreal | 0.00% | Add +531.6% | 92,530 | $331K |
| Renaissance Technologies | 0.00% | New | 26,300 | $94K |
| Geode Capital Management, LLC | 0.00% | Add +3.3% | 23,837 | $85K |
| Osaic Holdings, Inc. | 0.00% | Add +323.4% | 11,456 | $41K |
| Vanguard Group Inc. | 0.00% | No change | 10,504 | $38K |
| Wells Fargo & Company | 0.00% | Reduce -0.0% | 10,012 | $36K |
| BlackRock, Inc. | 0.00% | No change | 9,737 | $35K |
| UBS Group AG | 0.00% | Add +127.0% | 5,810 | $21K |
| Morgan Stanley | 0.00% | Add +13.6% | 4,015 | $14K |
| NFSG Corp | 0.00% | Add +57.1% | 2,750 | $10K |
| Clearstead Advisors, LLC | 0.00% | New | 865 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -51.0% | 450 | $2K |
| Jones Financial Companies LLLP | 0.00% | New | 300 | $1K |
| Elevation Point Wealth Partners, LLC | 0.00% | New | 46 | $165 |
| Bank of America Corp. | 0.00% | Add +7.4% | 29 | $104 |
| BNP Paribas Financial Markets | 0.00% | Add +166.7% | 16 | $57 |
| Blue Bell Private Wealth Management, LLC | 0.00% | No change | 10 | $36 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -25.0% | 6 | $21 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $4 |
| Allworth Financial LP | 0.00% | No change | 1 | $4 |
| Front Row Advisors LLC | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is GTBP's weight in each manager's 13F, not the share of GT Biopharma Inc. the manager owns.